Preparation and Characterization of Copper Oxide-Chitosan Nanocomposite for Colon-Targeted Drug Delivery System

This work aimed at synthesizing the chitosan-based nanocomposite for concurrent diagnosis of colon tumors and targeted drug shipping with minimum toxicity. CuO-chitosan nanocomposite was developed using CuO nanoparticles (NPs), chitosan raw materials and 1% acetic acid. FE-SEM/EDX, TEM, XRD, DLSUV-Vis, FT-IR, as well as fluorescent emission spectrum methods were used to investigate the characteristics of nanocomposite gained throughout distinct levels. Bovine serum albumin (BSA) protein release rate was estimated. We investigated the antibacterial functioning of the nanocomposite against different bacteria types (like S. aureus, S. typhi, E. coli, L. monocytogene and P. aeruginosa), which can affect in causing tense colonic diseases. Qualitative and quantitative surveys were performed. The impact of the nanocomposite on cancerous and normal human colon cell lines, specifically HCT-116 and SW-948, was examined using the MTT assay. Eventually, loading BSA onto the CuO-chitosan nanocomposite enhances its potential as a drug carrier for treating colon cancer, causing minimal harm to surrounding normal cells. Additionally, the CuO-chitosan nanocomposite demonstrated significant antibacterial activity against Escherichia coli, a key pathogen associated with Crohn's disease and ulcerative colitis.